Ophtec Secures CE Marking for Aspheric Presbyopia-Correcting IOL

May 12, 2017: By Jon Swedien

OphtecOphtec has received CE marking for its Precizon Presbyopic, a new aspheric presbyopia-correcting IOL, the Netherlands company announced May 6.

The lens will be commercially launched in October 2017 during the annual conference of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal.

The product will initially be available in the European Union and a few selected markets, Ophtec said.

The Precizon Presbyopic IOL features a patent-pending continuous transitional focus (CTF) optical design.

The CTF design’s transitional zones offer a smooth, continuous transition from near to infinity vision, enabling surgeons to treat a wider range of presbyopic patients with confidence, Ophtec said.

The IOL appears to be able to forgive larger degrees of lens tilt and decentration, and this tolerance reduces photic phenomena, helping patients to adapt more naturally to their new vision, Ophtec said.

The lens is also designed to be less dependent on pupil size under all lighting conditions, Ophtec said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Ophthalmic Devices Panel to hold Meeting Oct. 27

Novartis’ RTH258 Successful in Two Phase III Studies for nAMD

Ocugen Closes $7.5 Million Series B Round

Genentech Uses Vital Art and Science Vision-Testing App in Phase II Study of Sustained Delivery of Lucentis

US Supreme Court Ruling Shortens Time to Market for Biosimilars

Ellex Acquires Royalty Commitment for iTrack Device for $2.15 Million

Johnson & Johnson Vision Names Jonathan Talamo, MD, Chief Medical Officer

Teva Launches Generic Versions of Pataday in US

David Karcher Stepping Down as Executive Director, CEO of ASCRS

EyeGate Raises $10 Million in Public Offering

Aerie Raises $125 Million through Upsized Public Offering, ATM Program

pSivida’s Durasert for Posterior Segment Uveitis Successful in Second Phase III Study

Mynosys Zepto Receives US FDA 510(k) Clearance

Ozurdex, Humira Gain NICE Backing for Non-infectious Posterior Uveitis

Roger Steinert, Pioneer in Ophthalmology, Dies at 66

Carl Zeiss Meditec to Build New Innovation Center in Northern California

Gottlieb Says FDA to Publish List of Drugs Without Generic Competition

REGENXBIO Announces Phase I Clinical Trial for RGX-314 Gene Therapy for Wet AMD

Belkin Laser Closes Nearly $5 Million Financing Round

Valeant in Talks to Sell Surgical Business to Carl Zeiss Meditec

Coming soon

2017 Cataract Surgical Equipment: A Global Market Analysis for 2016 to 2022